Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study

Author:

Jacobson Karen R.1,Barnard Marinus2,Kleinman Mary B.3,Streicher Elizabeth M.4,Ragan Elizabeth J.1,White Laura F.5,Shapira Ofer6,Dolby Tania2,Simpson John2,Scott Lesley7,Stevens Wendy7,van Helden Paul D.4,Van Rie Annelies89,Warren Robin M.4

Affiliation:

1. Section of Infectious Diseases, Boston University School of Medicine, Massachusetts;

2. National Health Laboratory Service, Cape Town, South Africa;

3. Infectious Disease Prevention and Health Services Bureau, Prevention and Health Promotion Administration, Maryland Department of Health and Mental Hygiene, Baltimore;

4. Department of Science and Technology/National Research Foundation Centre of Excellence in Biomedical Tuberculosis Research/South Africa Medical Research Council for Molecular Biology and Human Genetics, Stellenbosch University, Tyberberg;

5. Department of Biostatistics, Boston University School of Public Health;

6. Department of Cancer Biology, Dana-Farber Cancer Institute, Cambridge, Massachusetts;

7. Department of Molecular Medicine and Haematology, School of Pathology, University of the Witwatersrand and National Health Laboratory Service, National Priority Program, Johannesburg, South Africa;

8. Department of Epidemiology, University of North Carolina, Chapel Hill;

9. Department of Epidemiology and Social Medicine and Epidemiology for Global Health Institute, University of Antwerp, Belgium

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Reference30 articles.

1. Point-of-care Xpert MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa;Van Rie;Int J Tuberc Lung Dis,2013

2. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study;Lawn;PLoS Med,2011

3. Diagnostic delays and clinical decision making with centralized Xpert MTB/RIF testing in Durban, South Africa;Cohen;J Acquir Immune Defic Syndr,2014

4. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients;Ahuja;PLoS Med,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3